Departments of Neurology and Psychology, University of Cincinnati, Suite 2300, Cincinnati, OH 45267, USA.
Parkinsons Dis. 2012;2012:603631. doi: 10.1155/2012/603631. Epub 2012 Apr 5.
The dopamine agonists ropinirole and pramipexole exhibit highly specific affinity for the cerebral dopamine D3 receptor. Use of these medications in Parkinson's disease has been complicated by the emergence of pathologic behavioral patterns such as hypersexuality, pathologic gambling, excessive hobbying, and other circumscribed obsessive-compulsive disorders of impulse control in people having no history of such disorders. These behavioral changes typically remit following discontinuation of the medication, further demonstrating a causal relationship. Expression of the D3 receptor is particularly rich within the limbic system, where it plays an important role in modulating the physiologic and emotional experience of novelty, reward, and risk assessment. Converging neuroanatomical, physiological, and behavioral science data suggest the high D3 affinity of these medications as the basis for these behavioral changes. These observations suggest the D3 receptor as a therapeutic target for obsessive-compulsive disorder and substance abuse, and improved understanding of D3 receptor function may aid drug design of future atypical antipsychotics.
多巴胺激动剂罗匹尼罗和普拉克索对大脑多巴胺 D3 受体表现出高度特异性亲和力。在帕金森病中使用这些药物时,出现了一些病理性行为模式,如性欲亢进、病理性赌博、过度癖好和其他特定的冲动控制障碍,而这些行为障碍在没有此类疾病史的人群中很少见。这些行为变化通常在停药后消失,进一步证明了它们之间存在因果关系。D3 受体在边缘系统中的表达特别丰富,在该系统中,它在调节新奇感、奖赏和风险评估的生理和情绪体验方面发挥着重要作用。神经解剖学、生理学和行为科学的综合数据表明,这些药物对 D3 受体的高亲和力是这些行为变化的基础。这些观察结果表明 D3 受体可能是强迫症和物质滥用的治疗靶点,并且对 D3 受体功能的更好理解可能有助于未来非典型抗精神病药物的药物设计。